December 2025
1. PINANDYO SH, Ali S, Aurelio B, Amoah AS, et al
   The association of helminth infection against antimalarial antibody responses in malaria infection and vaccination: a systematic review and meta-analysis.
   Vaccine. 2025;73:128125.
   

   >> Share

   
   November 2025
2. MUKHOPADHYAY ES, Bellamy DG, Tinto H, Hamaluba M, et al
   Corrigendum to "Naturally acquired immune responses to alpha-gal in malaria endemic settings and pre-clinical efficacy testing with R21/MM" [Vaccine 68 (2025) 127897].
   Vaccine. 2025;69:127973.
   

   >> Share

   
   
3. BIRKETT AJ, Ansah E, Gordon S, Gyapong M, et al
   Value profile for Malaria vaccines and monoclonal antibodies.
   Vaccine. 2025 Nov 15:127971. doi: 10.1016/j.vaccine.2025.127971.
   

   >> Share

   
   
4. MUKHOPADHYAY ES, Bellamy DG, Tinto H, Hamaluba M, et al
   Naturally acquired immune responses to alpha-gal in malaria endemic settings and pre-clinical efficacy testing with R21/MM.
   Vaccine. 2025;68:127897.
   

   >> Share

   
   October 2025
5. ANOSIKE C, Ojiakor IM, Etiaba EI, Uguru NP, et al
   Cost-effectiveness and budget impact of malaria, measles, and meningitis vaccines in Africa: a scoping review.
   Vaccine. 2025;67:127853.
   

   >> Share

   
   
6. BELMONTE M, Kusi KA, Kyei-Baafour E, Ofori EA, et al
   Immunogenicity of HLA-restricted peptide vaccine candidates delivered by self-assembling protein nanoparticle (SAPN) technology.
   Vaccine. 2025;66:127832.
   

   >> Share

   
   September 2025
7. ZHAO Z, Ma X, Milligan P, Cheung YB, et al
   Robust evaluation of vaccine effects based on estimation of vaccine efficacy curve.
   Vaccine. 2025;63:127673.
   

   >> Share

   
   July 2025
8. NJOH AA, Dinga JN, Kongnyuy EJ, Ndoula TS, et al
   Malaria vaccine acceptance and associated factors in cameroon: A nationwide cross-sectional survey.
   Vaccine. 2025;60:127323.
   

   >> Share

   
   June 2025
9. HASSAN IA, Araoye JB, Olawuyi DA, Effiong FB, et al
   Malaria vaccine implementation in Nigeria: Addressing the coverage challenges within the national immunization program for high impact.
   Vaccine. 2025;61:127376.
   

   >> Share

   
   May 2025
10. YUN SY, Nguyen MN, Hong H, Bae GJ, et al
    Immunogenicity and efficacy in mice of two adjuvant formulations based on the C -and N-terminus of merozoite surface protein 1 of Plasmodium yoelii.
    Vaccine. 2025;55:127032.
    

    >> Share

    
    April 2025
11. PARVEEN S, Rath PP, Tabrez S, Khan S, et al
    Novel, fully human, anti-PfCSP antibodies with potent antimalarial activity using a phage display based strategy.
    Vaccine. 2025;54:126993.
    

    >> Share

    
    
12. FERRERAS-COLINO E, de la Fuente J, Couto J, Golovchenko M, et al
    Immunostimulant effect of heat-inactivated Mycobacterium bovis in mice challenged with vector-borne pathogens.
    Vaccine. 2025;53:127076.
    

    >> Share

    
    
13. DESHMUKH B, Khatri D, Kochar SK, Athale C, et al
    In vitro evaluation of multi-protein chimeric antigens in effectively clearing the blood stage of Plasmodium falciparum.
    Vaccine. 2025;53:126952.
    

    >> Share

    
    
14. MO AX, McGugan G, Pesce JT
    Meeting report: Expert consultation on late arresting replication competent (LARC) malaria sporozoite vaccine research & development.
    Vaccine. 2025;54:127009.
    

    >> Share

    
    February 2025
15. SCALSKY R, Dwivedi A, Stabler TC, Mbambo G, et al
    Whole-genome sieve analysis: Identification of protective malaria antigens by leveraging allele-specific vaccine efficacy.
    Vaccine. 2025;50:126783.
    

    >> Share

    
    January 2025
16. CAO Y, da Silva Araujo M, Lorang CG, Dos Santos NAC, et al
    Distinct immunogenicity outcomes of DNA vaccines encoding malaria transmission-blocking vaccine target antigens Pfs230D1M and Pvs230D1.
    Vaccine. 2025;47:126696.
    

    >> Share

    
    October 2024
17. ZACHARIA MM, Ziema SA, Abanga WA, Kyeremeh RA, et al
    RTS, S malaria vaccination among children aged 24-59 months in the Sunyani Municipality, Ghana; 2023.
    Vaccine. 2024;42:126490.
    

    >> Share

    
    July 2024
18. SANGWE CN, Budzi MN, Shifu IN, Ghangha JG, et al
    The use of community-oriented primary care (COPC) model to generate vaccine demand: The case of a remote fishing community in Cameroon.
    Vaccine. 2024 Jul 31:126173. doi: 10.1016/j.vaccine.2024.126173.
    

    >> Share

    
    
19. CAO Y, Hayashi CTH, Araujo MDS, Tripathi AK, et al
    Evaluation of combination vaccines targeting transmission of Plasmodium falciparum and P. vivax.
    Vaccine. 2024 Jul 19:126140. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    May 2024
20. MERTENS JE, Rigby CA, Bardelli M, Quinkert D, et al
    Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development.
    Vaccine. 2024 May 3:S0264-410X(24)00514-0. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    
21. LAMBACH P, Silal S, Sbarra AN, Koh M, et al
    Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee (IVIR-AC) meeting, virtual gathering, 26 February-1 March 2024.
    Vaccine. 2024 May 3:S0264-410X(24)00494-8. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    April 2024
22. CUMMINGS JF, Polhemus ME, Kester KE, Ockenhouse CF, et al
    A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-naive adults.
    Vaccine. 2024 Apr 6:S0264-410X(24)00389-X. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    March 2024
23. MARQUES RF, Gimenez AM, Caballero O, Simpson A, et al
    Non-clinical toxicity and immunogenicity evaluation of a Plasmodium vivax malaria vaccine using Poly-ICLC (Hiltonol(R)) as adjuvant.
    Vaccine. 2024 Mar 5:S0264-410X(24)00229-9. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    February 2024
24. PLIESKATT J, Bang P, Wood GK, Naghizadeh M, et al
    Clinical formulation development of Plasmodium falciparum malaria vaccine candidates based on Pfs48/45, Pfs230, and PfCSP.
    Vaccine. 2024 Feb 21:S0264-410X(24)00202-0. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    
25. FABER BW, Yeoh LM, Kurtovic L, Mol WEM, et al
    A Diversity Covering (DiCo) Plasmodium vivax apical membrane antigen-1 vaccine adjuvanted with RFASE/RSL10 yields high levels of growth-inhibitory antibodies.
    Vaccine. 2024 Feb 16:S0264-410X(24)00175-0. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    November 2023
26. MOITA D, Nunes-Cabaco H, Rola C, Franke-Fayard B, et al
    Variable long-term protection by radiation-, chemo-, and genetically-attenuated Plasmodium berghei sporozoite vaccines.
    Vaccine. 2023 Nov 24:S0264-410X(23)01335-X. doi: 10.1016/j.vaccine.2023.
    

    >> Share

    
    
27. HAYASHI CTH, Cao Y, Zavala F, Simonyan H, et al
    Antibodies elicited by Plasmodium falciparum circumsporozoite proteins lacking sequentially deleted C-terminal amino acids reveal mouse strain and epitopes specific differences.
    Vaccine. 2023;41:6824-6833.
    

    >> Share

    
    August 2023
28. SHEARS MJ, Watson FN, Stone BC, Cruz Talavera I, et al
    Preliminary studies on the immunogenicity of a prime-and-trap malaria vaccine in nonhuman primates.
    Vaccine. 2023 Aug 8:S0264-410X(23)00913-1. doi: 10.1016/j.vaccine.2023.
    

    >> Share

    
    May 2023
29. SIMONS LM, Ferrer P, Gombakomba N, Underwood K, et al
    Extending the range of Plasmodium falciparum transmission blocking antibodies.
    Vaccine. 2023;41:3367-3379.
    

    >> Share

    
    April 2023
30. TOPAZIAN HM, Schmit N, Gerard-Ursin I, Charles GD, et al
    Modelling the relative cost-effectiveness of the RTS,S/AS01 malaria vaccine compared to investment in vector control or chemoprophylaxis.
    Vaccine. 2023 Apr 18:S0264-410X(23)00394-8. doi: 10.1016/j.vaccine.2023.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share